Adnan Malik

Dr. Adnan Malik

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2024 in Annals of Hepatology
Verified
Journal Article
Open access
AMAdnan Malik
Adnan Malik
SJSadia Javaid
Sadia Javaid
MMMuhammad Imran Malik
Muhammad Imran Malik
SQShahbaz Qureshi
Shahbaz Qureshi
Metabolic dysfunction-associated steatotic liver disease (MASLD) formerly known as Nonalcoholic fatty liver disease (NAFLD) is a common chronic disease. Identifying MASLD risk factors could help early intervention and reduce the burden of the disease. Previous studies investigated the association between sarcopenia and NAFLD. Several trials were published after the last meta-analysis with indecisive results. This is an updated meta-analysis which aims to assess the association between sarcopenia, MASLD, and MASLD-related fibrosis. Relevant trials published on PubMed, Web of Science, Scopus, and Cochrane Library databases until October 2022 were included. We included studies in which skeletal mass index (SMI) or sarcopenia was compared between patients with and without NAFLD now MASLD. Also, studies comparing fibrosis between MASLD patients with and without sarcopenia were included. Data were pooled as odds ratios (ORs) and 95% confidence intervals (CIs) using Review Manager Software. A total of 25 studies were included. The incidence of sarcopenia was significantly higher in MASLD than controls (OR, 1.25; 95% CI, 1.08-1.44; P = 0.003). SMI odds showed no significant difference between NAFLD patients and controls (OR, 1.02; 95% CI, 0.91-1.15; P = 0.7). NAFLD patients with sarcopenia had higher odds of fibrosis than NAFLD patients without sarcopenia (OR, 1.49; 95% CI, 1.03-2.14; P = 0.03). Sarcopenia increased MASLD's probability and was associated with a higher probability of liver fibrosis in MASLD patients. However, SMI had no predictive value of MASLD occurrence.

26 February 2024 in Canadian Liver Journal
Verified
Journal Article
Closed access
AMAdnan Malik
Adnan Malik
MMMuhammad Malik
Muhammad Malik
SQShahbaz Qureshi
Shahbaz Qureshi
Background: Fatty liver disease comprises a wide range of related liver disorders affecting mainly people who drink no or minimal amounts of alcohol. Silymarin is a member of the Carduus marianum family that has been used for centuries to treat different diseases. There is little evidence supporting its efficacy in humans. Objectives: To evaluate the effects of Silymarin in patients with non alcoholic fatty liver disease (NAFLD) or recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: We searched PubMed, SCOPUS, Web of Science, and Cochrane Library for relevant clinical trials assessing the use of silymarin in patients with NAFLD. A risk of bias assessment was performed using Cochrane's risk of bias tool. We included the following outcomes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (GGT), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) (mg/dL), degree of fibrosis resolution, low-density lipoprotein (LDL), and HOMA-IR. We analyzed continuous data using mean difference (MD) and relative 95% confidence interval (CI). Results: We included nine clinical trials. We found that silymarin significantly reduced the levels of ALT (MD= -17.12 [-28.81, -4.43]), (P < 0.004), AST (MD= -12.56 [-19.02, -6.10]), (P < 0.0001) and TG (MD = −22.60 [−23.83, −21.38]) ( p < 0.00001). It also improved HDL (MD= 2.13 [1.60, 2.66]), (P < 0.01)). There was no significant difference regarding GGT (P=o.07), TC (P= 0.52), LDL (P= 0.06), HOMA-IR (P= 0.06) and BMI (p=0.1).One study reported significant improvement in the degree of fibrosis (P = 0.023). Conclusion: Silymarin treatment significantly reduces biochemical and transaminase levels in patients with MASLD.

9 August 2021 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
AMAdnan Malik
Adnan Malik
MNMahum Nadeem
Mahum Nadeem
MMMuhammad Imran Malik
Muhammad Imran Malik

8 May 2024 in Canadian Liver Journal
Verified
Journal Article
Closed access
AMAdnan Malik
Adnan Malik
MMMuhammad Malik
Muhammad Malik
Background: Curcumin is an anti-inflammatory that is proposed to have a positive impact on patients with non-alcoholic fatty liver disease (NAFLD). We aim to assess the effects of curcumin in patients with NAFLD. Methods: Clinical trials from PubMed, Scopus, the Web of Science, and Cochrane CENTRAL with variables alanine transferase, aspartate transaminase, alkaline phosphatase, glycated hemoglobin (HBA1c), BMI, waist circumference, total cholesterol, total glycerides, high-density lipoproteins, and low-density lipoproteins were included. Homogeneous and heterogeneous were analyzed under a fixed-effects model and the random-effects model, respectively. Results: Fourteen clinical trials found that curcumin has no statistically significant effect on alanine transferase (MD = −2.20 [−6.03, 1.63], p = 0.26], aspartate transaminase (MD = 1.37 [−4.56, 1.81], p = 0.4), alkaline phosphatase (MD = 3.06 [−15.85, 9.73], p = 0.64), glycated hemoglobin (HBA1c), (MD = −0.06 [−0.13, 0.02], p = 0.16], and BMI (MD = 0.04 [−0.38, 0.46], p = 0.86). Curcumin reduced the waist circumference (MD = −4.87 [−8.50, −1.25], p = 0.008). Lipid profile parameters were not significant, except the total glycerides (MD = −13.22 [−24.19, −2.24], p = 0.02). Conclusions: Curcumin significantly reduces total glycerides and waist circumference in NAFLD.

14 February 2022 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AMAdnan Malik
Adnan Malik
MNMahum Nadeem
Mahum Nadeem
SJSadia Javaid
Sadia Javaid
MMMuhammad Imran Malik
Muhammad Imran Malik
IEIkponmwosa Enofe
Ikponmwosa Enofe
AAAyokunle T. Abegunde
Ayokunle T. Abegunde
Microscopic colitis (MC) is an inflammatory disease of the colon characterized by persistent watery, nonbloody diarrhea. Subtypes of MC include collagenous and lymphocytic MC. Microscopic examination of colon tissue is crucial to confirming the diagnosis because the colonic mucosa often appears normal during flexible sigmoidoscopy or colonoscopy. We aim to determine the optimal sites and minimum number of colon biopsies required to diagnose MC from published studies. We systematically searched PubMed, Web of Science, Scopus, and Cochrane databases from inception until October 2020 using the following keywords: microscopic, lymphocytic, collagenous, colitis, biopsy, and biopsies. We screened the search results for eligibility and extracted data from the included studies. We pooled the numbers of biopsies provided by each study to calculate the mean number of biopsies, SD, and SEM. We included three retrospective cohort studies with 356 patients (148 collagenous, 192 lymphocytic, and 16 mixed), and the total number of biopsies were 1854. The mean number of biopsies that were recommended by the included studies are 4, 4, and 9, respectively. The pooled mean ± SD is 5.67 ± 2.89. The included studies reported that biopsies from the ascending colon (AC) and descending colon (DC) had the highest diagnostic rates. To ensure a high level of certainty in diagnosing MC, a total of six biopsies should be taken from the AC and DC (3 AC and 3 DC). However, special care should be directed toward differentiating MC from other forms of colitis. In addition, detailed and comparative studies are needed to provide stronger recommendations to diagnose MC.

1 August 2023 in Gastroenterology Research
Verified
Journal Article
Open access
PDF file
AMAdnan Malik
Adnan Malik
MMMuhammad Imran Malik
Muhammad Imran Malik
Fecal Microbiota Transplantation in Human Immunodeficiency Virus-Infected Patient Population: A Systematic Review and Meta-Analysis